2015 Esc/Ers Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension

Galiè, Nazzareno; Humbert, Marc; Vachiéry, Jean‐Luc; Gibbs, Simon; Lang, Irene; Torbicki, Adam; Simonneau, Gérald; Peacock, Andrew J.; Vonk‐Noordegraaf, Anton; Beghetti, Maurice; Ghofrani, Hossein Ardeschir; Sánchez, Miguel; Hansmann, Georg; Klepetko, Walter; Lancellotti, Patrizio; Matucci, Marzia; McDonagh, Theresa A.; Piérard, Luc; Trindade, Pedro T.; Zompatori, Maurizio; Hoeper, Marius M.; Гончарова, Н. С.; Моисеева, О. М.

doi:10.15829/1560-4071-2016-5-5-64

Cited by 263 publications

(656 citation statements)

References 0 publications

Supporting

Mentioning

636

Contrasting

Unclassified

Order By: Relevance

“…72,96 Systolic pulmonary artery pressure is derived from an optimal recording of maximal tricuspid regurgitant jet and the tricuspid systolic gradient, together with an estimate of RA pressure on the basis of inferior vena cava (IVC) size and its breathing-related collapse. 97 RV size should be routinely assessed by conventional twodimensional echocardiography using multiple acoustic windows, and the report should include both qualitative and quantitative parameters. In laboratories with experience in three-dimensional echocardiography, when knowledge of RV volumes may be clinically important, three-dimensional measurement of RV volumes is recommended.…”

Section: Assessment Of Right Ventricular Function and Pulmonary Artermentioning

confidence: 99%

2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Ponikowski¹,

Voors²,

Anker³

et al. 2016

Revista Española de Cardiología (English Edition)

558

677

View full text Add to dashboard Cite

Section: Assessment Of Right Ventricular Function and Pulmonary Artermentioning

confidence: 99%

2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Ponikowski¹,

Voors²,

Anker³

et al. 2016

Revista Española de Cardiología (English Edition)

558

677

View full text Add to dashboard Cite

“…These patients must be evaluated by an experienced Heart Team and operated by surgeons familiar with the valve repair/replacement techniques. Double‐lung or heart‐lung transplantation are other possible approaches in these patients 5 …”

Section: Discussionmentioning

confidence: 99%

“…Idiopathic pulmonary arterial hypertension (IPAH) is an important cause of PAA formation 5 . In IPAH patients PAA may result in dissection, rupture, or compression of adjacent structures such as the left main coronary artery (LMCA), main bronchi, or the recurrent laryngeal nerve 5 . In this report, we describe our surgical approach to a patient with IPAH and a giant‐size PAA complicated with severe pulmonary regurgitation (PR) and symptomatic LMCA compression.…”

Section: Introductionmentioning

confidence: 99%

David's procedure for pulmonary artery aneurysm

et al. 2020

View full text Add to dashboard Cite

Pulmonary artery aneurysm (PAA) is a rare entity with fatal complications. Its silent course contributes to large aneurysms with compression symptoms. We present a 39‐year‐old female idiopathic pulmonary arterial hypertension patient with a giant PAA causing severe pulmonary regurgitation (PR) and symptomatic left main coronary artery compression (LMCA). Since she had a failed LMCA stenting attempt, she underwent surgery. A valve‐sparing David‐like pulmonary trunk reconstruction and coronary artery bypass were performed. This case illustrates that David‐like reconstruction procedure can be applied to the PAA with severe PR.

show abstract

“…Patients in the treatment-switch subgroup had received sildenafil (20–80 mg three times daily [TID]) before study baseline and were assessed as having an inadequate clinical response to sildenafil therapy (see Supplementary Information for further details). The decision to transition patients to riociguat was based on the national guidelines for diagnosis and treatment of pulmonary hypertension [14]. …”

Section: Methodsmentioning

confidence: 99%

Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling

Lyapina

Belevskaya

Saidova

et al. 2018

Lung

View full text Add to dashboard Cite

PurposeTo evaluate the influence of riociguat on World Health Organization functional class (WHO FC), 6-min walk distance (6MWD), right heart remodeling, and right ventricular–pulmonary arterial (RV–PA) coupling in patients with idiopathic pulmonary arterial hypertension (IPAH) who are treatment-naïve or who have failed to achieve treatment goals with sildenafil therapy.MethodsTwenty patients with IPAH were enrolled: 12 had not previously received PAH-targeted therapy (treatment-naïve subgroup) and 8 had been receiving sildenafil therapy but failed to achieve treatment goals; on entering this pilot study these 8 patients were switched from sildenafil to riociguat therapy (treatment-switch subgroup). Patients received riociguat individually dose-adjusted up to a maximum of 2.5 mg three times daily. After 12 weeks, patients were assessed for WHO FC, 6MWD, right heart remodeling, and RV–PA coupling.ResultsRiociguat significantly improved WHO FC in treatment-naïve patients (from 0/4/8/0 patients in WHO I/II/III/IV at baseline to 1/6/5/0 at week 12) and in treatment-switch patients (from 0/4/4/0 patients in WHO I/II/III/IV at baseline to 1/4/3/0 at week 12). Additionally, treatment-naïve and treatment-switch patients showed significant improvements at week 12 versus baseline in 6MWD (increases of + 76.8 m and + 71.6 m, respectively), RV systolic function, and RV–PA coupling.ConclusionThese results support the proven efficacy of riociguat in patients with IPAH, including treatment-naïve patients and those switching to riociguat following failure to achieve treatment goals with sildenafil, and suggest that it may be possible to delay disease progression in this patient group.Electronic supplementary materialThe online version of this article (10.1007/s00408-018-0160-4) contains supplementary material, which is available to authorized users.

show abstract

2015 Esc/Ers Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension

Cited by 263 publications

References 0 publications

2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

David's procedure for pulmonary artery aneurysm

Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling

Contact Info

Product

Resources

About